TITLE

Adverse Effects of Bisphosphonates: Implications for Osteoporosis Management

AUTHOR(S)
Kennel, Kurt A.; Drake, Matthew T.
PUB. DATE
July 2009
SOURCE
Mayo Clinic Proceedings;Jul2009, Vol. 84 Issue 7, p632
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Bisphosphonates are widely prescribed and highly effective at limiting the bone loss that occurs In many disorders characterized by increased osteoclast-mediated bone resorption, including senile osteoporosis In both men and women, glucocorticoid-associated osteoporosis, and malignancies metastatic to bone. Although they are generally well tolerated, potential adverse effects may limit bisphosphonate use In some patients. Optimal use of bisphosphonates for osteoporosis requires adequate calcium and vitamin D intake before and during therapy. The World Health Organization fracture risk assessment algorithm is currently available to determine absolute fracture risk In patients with low bone mass and Is a useful tool for clinicians in identifying patients most likely to benefit from pharmacological intervention to limit fracture risk. This fracture risk estimate may facilitate shared decision making, especially when patients are wary of the rare but serious adverse effects that have recently been described for this class of drugs.
ACCESSION #
42999324

 

Related Articles

  • Zoledronic Acid. Deeks, Emma D.; Perry, Caroline M. // Drugs & Aging;2008, Vol. 25 Issue 11, p963 

    Zoledronic acid (Aclasta®; Reclast®), a third-generation nitrogen-containing bisphosphonate, is the first once-yearly treatment to have been approved for use in patients with postmenopausal nsteoporosis or at high risk of fracture. Intravenous zoledronic acid 5 mg once yearly is effective...

  • Evolving Data about Subtrochanteric Fractures and Bisphosphonates. Shane, Elizabeth // New England Journal of Medicine;5/13/2010, Vol. 362 Issue 19, p1825 

    In this article, the author expresses her views on data related to subtrochanteric fractures and bisphosphonates, in relation to a study published in a May 2010 issue of the "New England Journal of Medicine." She explains the ability of bisphosphonates to reduce bone turnover markers and...

  • Who should have bisphosphonates? Woolf, Tony // Pulse;5/31/2004, Vol. 64 Issue 22, p60 

    Provides some insights into the use of bisphosphonates. Effectiveness in preventing fractures; Risk factors and indications; Osteoporosis; Diagnosis and treatment.

  • Osteoporosis.  // Current Medical Literature: Rheumatology;2008, Vol. 27 Issue 1, p21 

    The article discusses research being done on the use of a case manager to improve osteoporosis treatment after hip fracture. It references a study by S. R. Majumdar et al., published on a 2007 issue of the journal "Archives of Internal Medicine." The study found that the proactive use of a case...

  • The 5-year follow-up of a cortical stress fracture resulting in a spontaneous atypical subtrochanteric femoral fracture in a female patient with severe osteoporosis and bisphosphonate therapy over 15 years. Haschka, Judith; K�hne, Friederike; Muschitz, Christian; Pirker, Thomas; Kocijan, Roland; Bittighofer, Christina; Trubrich, Angela; Resch, Heinrich // Wiener Klinische Wochenschrift;Nov2011, Vol. 123 Issue 21/22, p684 

    Atypical fractures under long term treatment with bisphosphonates (BP) have been reported, although no causal connection has been known. As an explanation the suppression of bone turnover with poor bone metabolism and consequently deterioration of bone microarchitecture has been suggested. In...

  • Do bisphosphonates cause femoral insufficiency fractures? Seraphim, Andreas; Al-Hadithy, Nawfal; Mordecai, Simon; Al-Nammari, Shafic // Journal of Orthopaedics & Traumatology;Dec2012, Vol. 13 Issue 4, p171 

    In recent years, several reports have suggested an association between the use of bisphosphonates and subtrochanteric insufficiency fractures. Research from animal studies and in some cases from histomorphometric data collected from patients provide evidence of a possible pathophysiological...

  • Impact of Treatments for Postmenopausal Osteoporosis (Bisphosphonates, Parathyroid Hormone, Strontium Ranelate, and Denosumab) on Bone Quality: A Systematic Review. Gallacher, S. J.; Dixon, T. // Calcified Tissue International;Dec2010, Vol. 87 Issue 6, p469 

    The objective of this systematic review was to examine the influence of treatments for postmenopausal osteoporosis (parathyroid hormone [PTH], bisphosphonates, strontium ranelate, and denosumab) on bone quality and discuss the clinical implications. Most bone-quality data for PTH is from...

  • Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date. Hodsman, Anthony B.; Hanley, David A.; Josse, Robert // CMAJ: Canadian Medical Association Journal;5/28/2002, Vol. 166 Issue 11, p1426 

    Discusses whether bisphosphonates reduce the risk of osteoporotic fractures. Mortality from bone fractures in the elderly; Fracture rates among patients with osteoporosis; Indication that bisphosphonates increase bone mineral density; Expected reduction in morbidity and mortality.

  • TRATAMIENTO CON BISFOSFONATOS Y FRACTURAS ATIPICAS. Spivacow, Francisco R.; Sarli, Marcelo; Buttazzoni, Mirena // Medicina (Buenos Aires);2009, Vol. 69 Issue 6, p612 

    In the last twenty five years aminobisphosphonates have became the drugs of choice for the treatment of osteoporosis. They strongly inhibit osteoclastic bone resorption and reduce the incidence of new fractures in patients with established osteoporosis, but their long half-life and their chronic...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics